翻訳と辞書 |
GL-ONC1 GL-ONC1 is an investigational therapeutic product consisting of the clinical grade formulation of the laboratory strain GLV-1h68, an oncolytic virus developed by Genelux Corporation.〔 GL-ONC1 is currently under evaluation in Phase I/II human clinical trials in the United States and Europe.〔(【引用サイトリンク】title=Search of: GL-ONC1 - List Results - ClinicalTrials.gov )〕 GL-ONC1 is an attenuated vaccinia virus (Lister strain) that causes regression and elimination of a wide range of solid tumors in preclincal mouse models.〔(【引用サイトリンク】title=GLV-1h68 - PubMed - NCBI )〕 GLV-1h68 (GL-ONC1) was generated by insertion of three expression cassettes (encoding Renilla luciferase-Aequorea green fluorescent protein fusion, beta-galactosidase, and beta-glucuronidase) replacing the F14.5L, J2R (encoding thymidine kinase) and A56R (encoding hemagglutinin) loci of the parental viral Lister strain genome, respectively. The oncolytic virus specifically infects and kills tumor cells which leads to oncolysis, which is thought to trigger an anti-tumor immune response. ==Clinical trials==
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「GL-ONC1」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|